Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients
- Poster presentation: Background In the past years, once-daily (QD) dosing of antiretroviral combination therapy has become an increasingly available treatment option for HIV-1+ patients. Methods Open label study in which HIV-1+ patients treated with SAQ/RTV (1000/100 mg BID) and two NRTIs with HIV-RNA-PCR < 50 copies/ml were switched to SAQ/RTV(2000/100 mg QD) with unchanged NRTI-backbone. CD4-cells, HIV-RNA-PCR, SAQ and RTV drug-levels and metabolic parameters were compared. Summary of results 17 patients (15 male, 42 years), median CD4 456 ± 139/micro l were included so far. The median follow-up time is 4 months. The HIV-RNA-PCR remained <50 copies/ml for all patients. Fasting metabolic parameters remained unchanged. The SAQ AUC 0–12 h were significantly higher when given QD vs. BID (median 29,400 vs. 18,500 ng*h/ml; p = 0.009), whereas the Cmin, Cmax and AUC was lower for RTV when given QD vs. BID (7,400 vs. 11,700 ng*h/ml; p = 0.02). Conclusion In this ongoing study SAQ/RTV (2000/100 mg QD) was well tolerated and demonstrated higher SAQ and lower RTV drug levels as compared to the BID dosing schedule. (Table 1 and Figure 1.)
Verfasserangaben: | Markus Bickel, Alexander Bodtländer, Gaby Knecht, Michael Kurowski, Stefan Klauke, Thomas Lutz |
---|---|
URN: | urn:nbn:de:hebis:30-70671 |
DOI: | https://doi.org/10.1186/1758-2652-11-S1-P59 |
Titel des übergeordneten Werkes (Englisch): | Journal of the International AIDS Society |
Verlag: | Springer |
Verlagsort: | Berlin ; Heidelberg |
Dokumentart: | Wissenschaftlicher Artikel |
Sprache: | Englisch |
Datum der Veröffentlichung (online): | 20.09.2009 |
Datum der Erstveröffentlichung: | 10.11.2008 |
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Datum der Freischaltung: | 20.09.2009 |
Jahrgang: | 11 |
Ausgabe / Heft: | (Suppl 1):P59 |
Seitenzahl: | 2 |
Erste Seite: | 1 |
Letzte Seite: | 2 |
Bemerkung: | © 2008 Bickel et al; licensee BioMed Central Ltd. |
Quelle: | Journal of the International AIDS Society 2008, 11(Suppl 1):P59 ; doi:10.1186/1758-2652-11-S1-P59 ; from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9–13 November 2008 |
HeBIS-PPN: | 21887118X |
Institute: | Medizin / Medizin |
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Lizenz (Deutsch): | Deutsches Urheberrecht |